| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer
1 company
Hohl Benjamin is a Chief Financial Officer at Enliven Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 13 sells.
Estimated insider holdings value: $1.6M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 29, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $20.40 | $66,291.23 | -12.4% | -21.5% | - | |
| Aug 27, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $20.63 | $67,038.73 | -12.4% | +4.9% | - | |
| Jul 28, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $20.46 | $66,503.76 | -6.6% | +3.5% | - | |
| Jul 10, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,000 | $22.66 | $22,655.00 | -4.2% | -10.8% | - | |
| Jun 27, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $20.91 | $67,955.81 | -6.6% | -10.2% | - | |
| Jun 13, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,000 | $22.55 | $67,655.40 | -11.5% | -9.1% | +110.5% | |
| May 27, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $16.18 | $52,593.45 | -12.4% | +24.7% | +159.0% | |
| Apr 28, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $18.69 | $60,737.55 | -6.6% | +9.3% | +127.3% | |
| Mar 27, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,250 | $21.33 | $69,320.88 | -12.4% | -0.0% | +80.5% | |
| Mar 24, 2025 | ELVN Enliven Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 1,000 | $22.50 | $22,504.50 | -4.2% | -9.7% | +38.7% |